E-LIB Suche - Ergebnisse für: A. Eyre, Toby

1

Safety of Extended Pirtobrutinib Exposure in Relapsed and/o..:

Roeker, Lindsey E. ; Coombs, Catherine C. ; Shah, Nirav N....
Acta Haematologica. , 2024

Link: https://doi.org/10.1159/..

2

Pirtobrutinib, a highly selective, non-covalent (reversible..:

Wierda, William G ; Shah, Nirav N ; Cheah, Chan Y...
The Lancet Haematology. , 2024

Link: https://doi.org/10.1016/..

3

Immunogenicity of COVID‐19 vaccines in patients with follic..:

Lim, Yeong Jer ; Ward, Victoria ; Brown, Anthony...
British Journal of Haematology. , 2024

Link: https://doi.org/10.1111/..

4

An Updated Comparison of Overall Survival with Brexucabtage..:

Hess, Georg ; Dreyling, Martin ; Oberic, Lucie...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S359-S360 , 2024

Link: https://doi.org/10.1016/..

5

Ibrutinib as first-line therapy for mantle cell lymphoma: a..:

Tivey, Ann ; Shotton, Rohan ; Eyre, Toby A....
Blood Advances. 8 (2024) 5 - p. 1209-1219 , 2024

Link: https://doi.org/10.1182/..

6

Acalabrutinib-based regimens in frontline or relapsed/refra..:

Davids, Matthew S. ; Sharman, Jeff P. ; Ghia, Paolo...
Blood Advances. 8 (2024) 13 - p. 3345-3359 , 2024

Link: https://doi.org/10.1182/..

7

Impact of MYC and BCL2 double expression on outcomes in pri..:

Poynton, Edward ; Chernucha, Emily ; Day, James...
Blood Advances. 8 (2024) 7 - p. 1772-1775 , 2024

Link: https://doi.org/10.1182/..

8

Safety of bendamustine for the treatment of indolent non-Ho..:

Shotton, Rohan ; Broadbent, Rachel ; Alchawaf, Alia...
Blood Advances. 8 (2024) 4 - p. 878-888 , 2024

Link: https://doi.org/10.1182/..

9

The management of newly diagnosed large B‐cell lymphoma: A ..:

Fox, Christopher P. ; Chaganti, Sridhar ; McIlroy, Graham...
British Journal of Haematology. 204 (2024) 4 - p. 1178-1192 , 2024

Link: https://doi.org/10.1111/..

10

Limited efficacy for ibrutinib and venetoclax in T-prolymph..:

Herling, Marco ; Dearden, Claire ; Zaja, Francesco...
Blood Advances. 8 (2024) 4 - p. 842-845 , 2024

Link: https://doi.org/10.1182/..

11

POSTER: CT-166 Long-Term Safety With ≥12 Months of Pirtobru..:

Muehlenbein, Catherine E. ; Coombs, Catherine C. ; Shah, Nirav N....
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S229 , 2023

Link: https://doi.org/10.1016/..

12

POSTER: ABCL-184 Impact of MYC and BCL2 Double Expression o..:

Poynton, Edward ; Chernucha, Emily ; Day, James...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S200 , 2023

Link: https://doi.org/10.1016/..

13

P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-C..:

Scarfò, Lydia ; Patel, Manish R. ; Eyre, Toby A....
HemaSphere. 7 (2023) S3 - p. e852670f , 2023

Link: https://doi.org/10.1097/..

14

Real world reduction in red cell transfusion with restricti..:

Pervaiz, Omer ; Dhanapal, Jay ; Pillai, Lakshmi...
Transfusion Medicine. 33 (2023) 3 - p. 254-256 , 2023

Link: https://doi.org/10.1111/..

15

MCL-155 Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated..:

Wang, Michael L. ; Shah, Nirav N. ; Jurczak, Wojciech...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S459 , 2023

Link: https://doi.org/10.1016/..